Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Vitaros end-of-review meeting scheduled by FDA

March 27, 2018

Phase III efficacy and safety data reported for vibegron in overactive bladder

March 27, 2018

Lokelma receives E.U. approval for hyperkalemia

March 23, 2018

Boston Scientific to acquire NxThera

March 22, 2018

Eli Lilly discovers novel PDE1 inhibitors

March 22, 2018

Mereo announces topline phase IIb results for BGS-649 to treat hypogonadotropic hypogonadism

March 19, 2018

OxThera initiates phase III study of Oxabact in primary hyperoxaluria

March 15, 2018

Solifenacin oral suspension for pediatric patients approved in Europe

March 12, 2018

Phase II data presented from the STOP-AKI trial of recAP in sepsis-associated acute kidney injury

March 12, 2018

Allena initiates phase III trial of ALLN-177 in patients with enteric hyperoxaluria

March 7, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...